Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of Recombinant Human Clara Cell 10kDa Protein (rhCC10) Delivered Intratracheally to Premature Neonates With Respiratory Distress Syndrome

NCT01473264 is registered in ClinicalTrials.gov with Clarassance, Inc. as lead sponsor.

NCT NCT01473264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01473264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of Recombinant Human Clara Cell 10kDa Protein (rhCC10) Delivered Intratracheally to Premature Neonates With Respiratory Distress Syndrome
Lead sponsor
Clarassance, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2000
Completion date
December 31, 2003
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bronchopulmonary dysplasia, respiratory distress syndrome in premature infant